Medytox Inc. - Aug 12, 2021 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
10%+ Owner
Signature
/s/ Minjung Choi, Senior Manager, on behalf of Medytox Inc.
Stock symbol
EOLS
Transactions as of
Aug 12, 2021
Transactions value $
-$116
Form type
4
Date filed
2/6/2023, 03:18 PM
Previous filing
Aug 13, 2021
Next filing
Aug 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock, $0.00001 par value per share Purchase $253K +23K +0.32% $10.99 7.28M Aug 12, 2021 See Footnote F1, F2, F4
transaction EOLS Common Stock, $0.00001 par value per share Purchase $156K +14K +0.19% $11.11 7.3M Aug 13, 2021 See Footnote F1, F3, F4
transaction EOLS Common Stock, $0.00001 par value per share Sale -$409K -37K -0.51% $11.04 7.26M Jan 20, 2023 See Footnote F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Inadvertently filed late due to an administrative error.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive.
F4 The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership.